Open Access

Surgical management of abdominal and retroperitoneal Castleman's disease

  • Pascal Bucher1Email author,
  • Gilles Chassot1,
  • Guillaume Zufferey1,
  • Frederic Ris1,
  • Olivier Huber1 and
  • Philippe Morel1
World Journal of Surgical Oncology20053:33

DOI: 10.1186/1477-7819-3-33

Received: 28 February 2005

Accepted: 07 June 2005

Published: 07 June 2005

Abstract

Background

Abdominal and retroperitoneal Castleman's disease could present either as a localized disease or as a systemic disease. Castleman's disease is a lymphoid hyperplasia related to human Herpes virus type 8, which could have an aggressive behavior, similar to that of malignant lymphoid neoplasm mainly with the systemic type, or a benign one in its localized form.

Methods

The authors report two cases of localized Castleman's disease in the retroperitoneal space and review the current and recent progress in the knowledge of this atypical disease.

Cases presentation

The two patients were young healthy women presenting with a hyper vascular peri-renal mass suggestive of malignant tumor. Both have been resected in-toto. One of them had an extensive resection with nephrectomy, while the second had a kidney preserving surgery. Pathological examination revealed localized Castleman's disease and surgical margins were free of disease. Postoperative course was uneventful, and after more than 5-years of follow-up no recurrences have been observed.

Conclusion

Localized Castleman's disease should be considered when facing a solid hypervascular abdominal or retroperitoneal mass. A better knowledge of this disorder and its characteristic would help surgeon to avoid unnecessarily extensive resection for this benign disorder when dealing with abdominal or retroperitoneal tumors. Surgical resection is curative for the localized form, when complete, while splenectomy could be indicated for the systemic form.

Background

Castleman's disease (CD) is a rare lymphoid disorder where pathogenesis is a lymphoid tissue hyperplasia related to chronic herpes virus infection. It has been described in nearly every lymph node basin since it first description by B. Castleman in 1956 [1, 2]. Two basic pathologic types of this disease could be encountered: the hyaline vascular (HV) and the plasma cell (PC) types. The first tends to be localized in one lymph node and asymptomatic; the second has a more aggressive course and tends to be multifocal with systemic manifestations.

The authors' present two cases of localized Castleman's disease arising in the peri-renal space and review previous reports abdominal and retroperitoneal CD. A review of literature on Castleman's disease pathogenesis, clinical and radiological characteristics as well as its treatment is also included in this manuscript.

Case presentation

Case 1

A 33-years-old woman with no significant past medical history complained of abdominal right upper quadrant discomfort associated with an history of weight lost (8 kg over 2 months). Physical examination revealed a right upper quadrant mass on deep palpation. Routine hematology and blood biochemistry were normal. The patient was HIV1-2 negative. Chest and abdominal roentgenograms were considered normal. Abdominal ultrasonography (USG) revealed a large hypoechogenic mass, with regular border in the right anterior peri-renal space. Computed tomography (CT) scan showed a 10 × 8 cm mass with regular contour, containing small calcifications, which strongly enhanced with vascular contrast. The lesion was in contact with the right kidney and ureter. Surgery was planned with a preoperative diagnosis of malignant retroperitoneal tumor versus lymph node hyperplasia.

Through a right transverse incision, after mobilization of the duodeno-pancreatic bloc, a tumor was found in contact of the right kidney, ureter and caval vein. While the possibility of malignancy could not be neglected, the mass was dissected en-bloc with wide margin in peri-renal fat. To allow free surgical margin clinically a segment of the right ureter as well as inferior pole of kidney were also excised en bloc. A right nephrectomy was finally performed latter on as the ureteral defect could not be repaired.

Histopathological examination of resected specimen revealed localized Castleman's disease of the hyaline vascular type. Patient had smooth postoperative recovery and is free of disease more than 6 years after resection.

Case 2

A 25-year-old woman with no significant past medical history, presented with post-prandial epigastric discomfort evolving over 2 years and post-prandial vomiting since 1 month. The patient reported 2.5 kg weight loss over 2 months. Physical examination revealed a left para-renal mass on deep palpation. Blood analyses were not relevant. CEA and CA19-9 were in the normal range. The patient was HIV1-2 negative. Chest and abdominal X-ray films were considered normal. An upper abdominal barium follow through was considered normal. Abdominal ultrasonography revealed a 6 cm diameter hypoechogenic mass in the left peri-renal space. CT scan showed a 6 × 7 cm mass, containing multiple small calcifications, which was highly hypervascular and regular in shape (figure 1). An arteriography confirmed the presence of hypervascularity with flushing of the mass (figure 2). Surgery was planned with a preoperative diagnosis of malignant retroperitoneal tumor.
Figure 1

Computed tomography scanner showing a large left-pararenal mass (Hyalin-vascular type of Castleman's disease). Note the presence of microcalcification (white spot) within the mass.

Figure 2

Arteriography showing the presence of a hypervascular mass (Hyalin-vascular type of Castleman's disease) with rapid flushing of the tumor. The feeding vessels originated from the aorta and left renal artery.

At laparotomy a 7 cm diameter mass was found in the left anterior peri-renal space, just inferior to the renal artery. The lesion was completely excised with what seems, clinically, to be a capsule. No organ resection was needed.

Pathologic diagnosis was localized Castleman's disease of the hyaline vascular type. Patient had had a simple postoperative period, except of persisting lumbar pain, attributed to a small inferior renal infarct (confirmed by CT scan). The patient is free of disease 5-years after resection.

Discussion

Castleman's disease (CD), also known as angiofollicular lymph node hyperplasia, was first reported by Symmers in 1921 [3]. This pathology was characterized by B. Castleman in 1956 as a benign lymph node hyperplasia resembling a thymoma [1, 2]. Keller et al identified two pathologic types of CD in 1972 [4]. First the hyaline vascular (HV) type which present as a pathological and extensively hypertrophied lymph node. Macroscopically it appears as an encapsulated homogenous mass with an orange-yellowish color. Microscopically, it is characterized by giant lymph follicles centered on a central vessel with marked hyalinization. Follicles are surrounded by circumferentially arranged layer, in an onion skin feature, of small polyclonal B-lymphocytes. These pathologic lymph nodes present a strong hypertrophied vascular arborescence [48]. The plasma cell (PC) type has the same macroscopic aspect as HV type, but contains much more mature polyclonal plasma cells with a less marked hyalinization and vascularization [4, 68]. It been shown that this two types histology are not always clearly separated and that mixed HV-PC types can also occur [7]. The histology of PC type is not specific of systemic CD and can be found in autoimmune disease, AIDS and in lymph nodes draining carcinoma, so it is imperious to exclude this condition before diagnosing CD of PC type [5, 6]. This implies that serologic testing for HIV should be performed whenever a diagnosis of CD is contemplated[5, 6].

The etiology of CD is related to chronic Human Herpes virus 8 (HSV8) [7] as HSV8 has been found in lymphoid cells in case of systemic form, or PC type, of Castleman's disease [9]. Its nature is not neoplastic as confirm by the fact that the lesion are made of a polyclonal proliferation [6, 7]. It's seems that CD is the result of a chronic low grade inflammatory process triggered by latent infection with HSV8, which leads to lymphoid system hyperplasia [57]. Human herpes virus 8 (HSV8), also called Kaposi's sarcoma-associated herpes virus (KHSV) is the initiator of this chronic inflammation by establishing a chronic or latent infection in lymph nodes [7]. Chronic infection by HSV8 stimulates secretion of IL-6 which in turn induces a hyperplasic reaction of the lymphoid system [6, 7]. While this lymphoid hyperplasia could be contained in one lymph node as in the localized form, which is mainly of HV type, it could also be generalized as in the systemic, or multifocal, form which is the predominant form for the PC type [6]. The patient's immunological status seems to play a major role in the development of these two forms. While localized form is encountered mainly in immunocompetent patients, the systemic form is found in patient with AIDS or other immunodeppression related either to immunosuppression or pathological state [6].

The localized form of CD arises predominantly in the mediastinum, where it was first described by B. Castleman [1]. However, it can be found in the neck, abdomen, axilla, inguinal region and in virtually all lymph node area [5, 7, 8, 10, 11]. Even non-nodal tissue could be involved, as is has been described in: lung, pancreas, breast, adrenal gland, muscle and other extremely rare locations [4, 7, 10, 11]. Testa et al [11] have reported the location of 315 cases of localized CD, 65% were in the mediastinum, 16% in the neck, 12% in the abdomen, 3% in the axilla and 4% in diverse locations.

A literature review of the abdominal and retroperitoneal case of localized HV type of CD has been done. In 1992, 54 abdominal and retroperitoneal cases were reviewed by Seco et al [5]. Now 195 cases of localized CD have been reported, in the world literature, arising in the abdomen and retroperitoneum. Of these 195 cases, 122 (63%) were in the retroperitoneum and 73 (37%) in the abdominal cavity (Table 1). Of the 122 lesions localized in the retroperitoneum, 24 (20%) were in the peri-renal region, as were our cases. Nearly all this lesions were derived from lymph node tissue, but 5 of these 195 cases (2%) seem to have originating in extra lymphoid organ. Three pancreatic, and one each of splenic and adrenal CD have been described [5860, 65, 80].
Table 1

Abdominal and retroperitoneal case of localized Castleman's disease (HV type)

Location

Number of cases

Authors

Retroperitoneu m

97

Seco et al [5], Bapat et al [12], Yamakita et al [13], Morishita et al [14], Genoni et al [15], Ng et al [16], Baikovas et al [17], Johnson et al [18], Martino et al [19], Guglielmi et al [20], Ziv et al [21], Gheysens et al [9], Halvic et al [22], Herrada et al [23], Furuhata et al [24], Ebine et al [25], Sadamoto et al [26], Gravalos et al. [27], Iwamoto et al [28], Sanna et al [29], Singletary et al [30], Curciacrello et al [31], Gonzalez Sanchez et al [32], Schutz et al [33], Perez Garcia et al [34], Irsutti et al [35], Parez et al [36], Buchanan et al [37]

Peri-renal

24

Ebisno et al. [38], Inoue et al. [39], Takihara et al. [40],,Feudis et al [41], Barret et al. [42], Okada et al [43], Present two cases

Mesentery

27

Seco et al. [5], Barki et al. [44], Hung et al. [45], Schroff et al. [46], Makipernaa et al. [47], De Heer-Groen et al [48], Parez et al [36], Neerhout et al [49], Powel et al [50], Burke et al [51]

Greater omentum

3

Volta et al [52], Kiguchi et al [53]

Gastric

2

Kiguchi et al [53], Yebra et al [54]

Peri-pancreatic

5

Kiguchi et al [53], Rotman et al [55], Brossard et al [56], Inoue et al [39], Erkan et al [57]

Pancreatic

3

Chaulin et al [58], Corbisier et al [59], Lepke et al [60]

Porta hepatitis

5

Rahmouni et al [61], Farkas et al [62], Peck et al [63], Cirillo et al [64]

Adrenal gland

1

Debatin et al [65]

Pelvis

27

Seco et al [5], Latte et al [66], Daley et al [67], Boxer et al. [68], Tsukamoto et al [69], Luburich et al [70], Isik et al [71], Ylinen et al [72], Schwartz et al [73], Mondal et al [74], Kiguchi et al [53], Calvo Villas et al [75], Mac Donald et al [76], Fields et al [77], Kkasantikul et al [78], Halvic et al [22], Murphy et al [79]

Spleen

1

Taura et al [80]

Total of cases

195

 
The clinical presentations of CD differ greatly between the localized and the systemic forms (Table 2). The first appears in young generally healthy patients and cause few symptoms [6, 7]. Abdominal and retroperitoneal locations, as were our cases, can be associated with mass effect symptoms related to compression of adjacent organs. This could present as: post-prandial discomfort, anorexia, vomiting, weight loss, urinary retention and abdominal or lumbar pain [80]. Systemic, or multifocal, CD is associated with systemic disturbance as anemia, increased erythrocyte sedimentation rate, polyclonal hypergammaglobulinemia, hypoalbuminemia and thrombocytopenia which all can be associated with a specific symptoms [68]. The clinical picture includes asthenia, fever, weight loss, generalized lymphadenopathy, hepatomegaly, splenomegaly, peripheric edema, pleural effusion, impaired renal function and sometimes polyneuropathy [68]. Rarely POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M protein and Skin change) or amyloidosis may be associated to systemic CD [68].
Table 2

Clinical forms of Castleman's disease

 

Localized form

Multifocal form

Mean age (years)

3rd decade

6th decade

Clinical signs

Incidental mass effect

Systemic symptoms

Localization

Mediastinum, cervical or abdominal, etc...

Multifocal, mostly peripheric lymph nodes

Histologic type

HV, rarely HV-PC

PC

Treatment

Surgical resection

Corticosteroids, chimiotherapy, radiotherapy

Prognosis

Excellent: 100% survival at 5 years

Poor: median survival of 30 months

Recurrence after treatment

Extremely rare, related to incomplete resection

Nearly always

Association

Rarely lymphoma

Frequent: AIDS, Kaposi's sarcoma, lymphoma and myeloma

Table adapted according to references: [5, 6, 7, 11]

Radiographic characteristics of CD are non specific, but some features could help to suspect the diagnosis (Table 3) [77, 80]. Plain radiographic finding includes a mass effect and in nearly 30% of localized form calcifications harboring a radial arrangement or star-shaped calcifications which is said to be characteristic of CD [77]. Ultrasonography (US) usually demonstrates a hypoechogenic and homogenous mass with quite clear delimitation [8, 30, 77]. US can show central areas of sharp acoustic shadowing due to calcification [30]. CT scan show a solid, homogenous and well delimited mass which enhance with vascular contrast as a results of hypervascularity [5, 30, 77, 80]. It can also show star-shaped microcalcifications which are quite specific on pre-contrast images [5, 27, 77]. Post-contrast IV study, while demonstrating dense enhancement of the mass, could demonstrate a central stellate scar [30, 80]. Angiography shows a strongly hypervascular lesion, which present a dense and homogenous flush during the capillary phase [5, 6, 8, 40, 53, 77, 80]. This flush begins in periphery to become diffuse whiting the mass and is specific for the HV type of CD [77, 80]. It can also demonstrate hypertrophied feeding vessel, an useful information when resection is plan [8, 53, 77, 80]. Magnetic resonance imaging (MRI) characteristics of CD are: hypodense mass on the T1 weighted study and hyperdense lesion on the T2 weighted image sometimes with star-shaped calcifications [60, 77, 80]. Gadolinium injection produces an enhancement which appear in periphery to become diffuse similarly to the flush observed during angiography [77, 80]. All these radiological finding are not specific but some like the star-shaped calcifications and the type of hypervascularisation are quite specific and should alert clinician to the possibility of CD. In summary, in front of an abdominal or retroperitoneal mass which is well delimited, homogenous and harbor star-shaped calcifications and hypervascularisation associated with typical flush, the diagnosis of CD should be strongly suspected [53, 77, 80]. The differential radiological diagnosis is mainly malignant neoplasm because of the hypervascularity [40, 77], and the fact that 80% of the retroperitoneal tumor are malignant [40, 81, 82]. The major tumors found in the retroperitoneum are soft tissue sarcoma (liposarcoma, fibrosarcoma, leiomyosarcoma, neurofibrosarcoma, undifferentiated and rabdomyosarcoma) which are frequently heterogeneous mass and show necrosis on CT scanner; vascular tumor (hemangiosarcoma and lymphangiosarcoma) which are cystic and of liquid density on USG and CT scanner; and the lymphoma which generally presents as multiple adenopathy and homogeneous mass on CT scanner [30, 8386]. Urological tumors like seminoma, prostatic cancer and teratoma tends to give rise to metastatic disease in the retroperitoneum in the form of adenopathy which are generally multiple [86]. While a preoperative diagnosis of CD is difficult to obtain, fine needle biopsy is not a definitive tools because of there low specificity and the differential diagnosis with lymphoma is impossible by this approach [77, 88]. In addition to be non-specific and rarely yielding enough useful tissue, needle biopsy is associated with tumoral seeding with reported frequency of 1/40 000 to 1/1 000 biopsy [83, 89]. Thus when surgery is planned, indication for fine needle biopsy should be carefully deliberated, while an open biopsy could always be done during surgery [83].
Table 3

Radiological characteristics of Castleman's disease

 

Non specific signs

Specific signs

Radiography

calcification.

Star-shaped calcification.

Echography

Hypoechogenic and homogenous mass. Central areas of acoustic shadowing (calcification).

 

CT scanner

Tissue density, Homogenous and well delimited mass. Contrast enhancement beginning in periphery.

Star-shaped microcalcifications Star-shaped scar on post-contrast study.

Arteriography

Hypervascularity with hypertrophied feeding vessel.

Flush beginning in periphery to become diffuse and homogenous during capillary phase.

MRI

Hypodense on T1 and hyperdense on T2. Contrast enhancement beginning in periphery.

Star-shaped microcalcification or star-shaped hypodense signal on T2.

Table adapted according to references: [5,9,27,30,34,42,48,65,]

Treatment of CD differs between localized and multifocal, or systemic, forms. The standard therapy of localized form is surgical excision which is curative when resection is complete and en-bloc. No recurrences have been reported after total excision in the literature as it was the case with our cases [57, 11, 38, 40, 53, 82, 90]. Because these lesions are highly vascularised, embolization before surgery could be helpful to minimize blood lost during surgery [5, 53]. The problem that is faced during resection is to resolve the differential diagnose between a malignant pathology and CD. Macroscopically it is nearly impossible because CD lesions harbor dense fibrous adherences to adjacent organ and hypervascularization typically seen in malignant pathology [5, 38, 82, 90]. For this reason peroperative diagnosis by open biopsy is helpful, and necessary in case of CD suspicion. It enables one to avoid extensive resection and especially resection of nearby organ for this benign disorder which does not invade adjacent organ even in case of tight contact [38, 82, 83, 90]. The five years survival after resection is nearly 100% for the localized form [6]. Recurrences have rarely been reported generally when excision was incomplete [6, 38, 82, 90]. For the systemic form no curative therapies have been found yet. Corticotherapy, immunosuppressive drugs, chemotherapy and radiotherapy have been tried without any convincing results [57, 91, 92]. The prognosis of this form is poor with a median survival of 30 months [6]. However recently, the reports of improvement and prolonged survival after splenectomy have been reported with steroid therapy and chemotherapy this could change the prognosis of the systemic form in the future [91, 92]. Of importance from the surgical point of view is that in these cases the remission was obtained after splenectomy only [91]. The systemic, PC type, and extremely rarely the localized, HV type, forms are associated with malignant disorder such as Kaposi's sarcoma, malignant lymphoma and myeloma. This association is stronger in HIV positive patients with CD, for example Kaposi's sarcoma is associated to 13% of case of PC type CD in HIV negative and in 75% of case when HIV positive patients. The association with Kaposi's sarcoma could be explained by the fact that HSV8 is cause in the pathogenesis of these two disorders [7]. These neoplasms can appear as late as 8 years after the diagnosis of CD, so a long term follow-up is required in patient in whom the diagnosis of CD has been established [6].

Conclusion

Castleman's disease (CD) is a rare lymphoid disorder, where etiology is related to Human herpes virus 8. CD could present in two forms: the localized (hyaline vascular type) and the systemic (plasma cell type). The localized hyaline vascular form has a unique indolent lymph node hyperplasia; which can be found in the abdomen, retroperitoneum or any lymph node basin; as a solitary mass. Localized CD is radiologically nearly undistinguishable from malignant neoplasms but some characteristics are quite specific, like the type of hypervascularization and the star-shape microcalcifications. A good preoperative work-up and an open biopsy during surgery, for abdominal and retroperitoneal mass if no diagnosis has been establish, can help to avoid extensive resection when facing this benign disorder. Complete surgical excision is curative; recurrences have only been described after incomplete resection. The prognosis is excellent with a five years survival of nearly 100%.

List Of Abbreviations

CD: 

Castleman's Disease

HV: 

Hyaline vascular type (of Castleman's disease)

PC: 

Plasma cell type (of Castleman's Disease)

CT scan: 

Computed tomography scanner

US: 

Ultrasonography

Declarations

Acknowledgements

Patients consent was obtained for publication of these case reports.

Authors’ Affiliations

(1)
Clinic of Visceral and Transplantation Surgery, Department of Surgery, Geneva University Hospital

References

  1. Castleman B: Case report of the Massachusetts General Hospital. N Engl J Med. 1954, 250: 26-30.View ArticleGoogle Scholar
  2. Castleman B, Iverson L, Menendez VP: Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956, 9: 822-830.View ArticlePubMedGoogle Scholar
  3. Symmers D: Primary hemangiolymphoma of the hemal nodes: an unusual variety of malignant tumour. Arch Intern Med. 1921, 28: 467-474.View ArticleGoogle Scholar
  4. Keller AR, Hochholzer L, Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972, 29: 670-683.View ArticlePubMedGoogle Scholar
  5. Seco JL, Velasco F, Manuel JS, Serrano SR, Tomas L, Velasco A: Retroperitoneal Castleman's disease. Surgery. 1992, 112: 850-855.PubMedGoogle Scholar
  6. Shahidi H, Myers JL, Kvale PA: Castleman's disease. Mayo Clin Proc. 1995, 70: 969-977.View ArticlePubMedGoogle Scholar
  7. Larroche C, Cacoub P, Godeau P: La maladie de Castleman. Rev Med Interne. 1996, 17: 1003-1013.View ArticlePubMedGoogle Scholar
  8. Gheysens B, Baste JC, Midy D, Pheline P, Alessandrin JF, Parrens M, De Mascarel A: La maladie de Castleman retroperitoneale. A propos d'une nouvelle observation. J Chir. 1994, 131: 492-495.Google Scholar
  9. Cesarman E, Knowles DM: The Role of Kaposi's sarcoma-associated herpesvirus (KHSV/HHV-8) in lymphoproliférative diseases. Semin Cancer Biol. 1999, 9: 165-174. 10.1006/scbi.1998.0118.View ArticlePubMedGoogle Scholar
  10. Von Schwarzenberg H, Wacker HH, Elfeldt RJ, Brinkmann G, Heller M: Morbus Castleman: Auswertung von 338 Fällen. Fortschr Röntgenstr. 1995, 163: 474-479.View ArticleGoogle Scholar
  11. Testa P, Pigne A, Voinnesson A, Vieillefond A, Paillas J: Les hyperplasies lymphoïdes angiofolliculaires (maladie de Catsleman) Premiere localisation meso-sigmoïdienne. Chirurgie. 1980, 106: 156-160.Google Scholar
  12. Bapat KC, Malde HM, Pandit AA, Mittal BV, Kedar RP, Bapat RD, Relekar RG: Solitary retroperitoneal angiofollicular lymph node hyperplasia. J Postgrad Med. 1992, 38: 90-94.PubMedGoogle Scholar
  13. Yamakita N, Sugimoto M, Takeda N, Goto S, Yasuda K, Uno H, Schimokawa K, Miura K: Pseudo-adrenal incidentaloma: magnetic resonance imaging in a patient with para-adrenal Castleman's disease. Urol Int. 1992, 49: 171-174.View ArticlePubMedGoogle Scholar
  14. Morishita H, Kobayashi T, Kunimi K, Amano T, Koshida K, Uchibayashi T, Hisazumi H, Naito K: A case of retroperitoneal Castleman's disease associated with bladder tumour and a review of 59 cases in Japan. Hinyokika kiyo. 1992, 38: 1041-1044.PubMedGoogle Scholar
  15. Genoni M, De Lorenzi D, Bogen M, Sulmoni A, Marone C, Alerci M, Pedrinis E, Muller W: Morbus Castleman. Dtsch Med Wochenschr. 1993, 118: 1316-1320.View ArticlePubMedGoogle Scholar
  16. Ng SH, Ko SF, Wong HF, Ng KK, Tsai CC: Retroperitoneal Castleman's disease: report of two cases. J Formos Med Assoc. 1993, 92: 482-484.PubMedGoogle Scholar
  17. Baikonas S, Glenn D, Stanton A, Vonthethoff L, Morris DL: Castleman's disease: An unusual cause of a peri-pancreatic hilar mass. Aust N Z J Surg. 1994, 64: 219-221.View ArticleGoogle Scholar
  18. Johnson WK, Ros PR, Powers C, Stoupis C, Segel KH: Castleman disease mimicking an aggressive retroperitoneal neoplasm. Abdom Imaging. 1994, 19: 342-324.PubMedGoogle Scholar
  19. Martino G, Stanzani GL, Cariati S, Elmore U, Tumino G, Zelli GP: Nell'ambito dei tumori rari retroperitoneali in eta geriatrica. A proposito di un caso di sindrome di Castleman. Ann Ital Chir. 1995, 66: 521-529.PubMedGoogle Scholar
  20. Guglielmi A, Boni M, Pelosi G, De Manzoni G, Frameglia M, Girlanda R: Malattia di Castleman retroperitoneale. Presentazione di un caso clinico. Ann Ital Chir. 1996, 67: 565-569.PubMedGoogle Scholar
  21. Ziv Y, Shikiar S, Segal M, Orda R: Bilateral localized Castleman disease of the retroperitoneum. Eur J Surg Oncol. 1993, 19: 188-191.PubMedGoogle Scholar
  22. Halvic N, Cornu P, Mosiman F: Maladie de Castleman: deux observations inhabituelles. Schweiz Med Wochenschr. 1998, 128: 331-336.Google Scholar
  23. Herrada J, cabanillas F, Rice L, Manning J, Pugh W: The clinical behaviour of localised and multicentric Castleman disease. Ann Intern Med. 1998, 128: 657-662.View ArticlePubMedGoogle Scholar
  24. Furuhata S, Sakai N, Yamada T, Murayama T, Asao T: Retroperitoneal Castleman's disease: a case report. Hinyokika Kiyo. 1998, 44: 163-166.PubMedGoogle Scholar
  25. Ebine Y, Serizawa H, Takaishi H, Watanabe N, Hamada Y, Kumagai N, Tsuchimoto K, Yamada Y, Toyoda H, Watanabe K, Morinaga S, Ishii H: Two cases of Castleman's disease originated in the retroperitoneum. Nippon Shokakibyo Gakkai Zasshi. 1998, 95: 250-256.PubMedGoogle Scholar
  26. Sadamoto Y, Abe Y, Higuchi K, Kato K, Matsumoto S, Arima N, Nawata H: Retroperitonel Castleman's disease of the hyaline vascular type presenting arborising calcification. Intern Med. 1998, 37: 691-3.View ArticlePubMedGoogle Scholar
  27. Gravalos GMR, Gual BJ, Moneva PE, Encina OJ, Sanz RLA: Rare origin of a retroperitoneal mass: Castleman's disease. Actas Urol Esp. 1998, 22: 542-545.Google Scholar
  28. Iwamoto Y, Ueda H, Yamamoto K, Kiura H, Itoh S, Hirai K, Takasaki N, Katsuoka Y: Retroperitoneal Castleman's disease occurred around the bilateral upper ureters. A case report. Nippon Hinyokika Gakkai Zasshi. 1998, 89: 618-621.PubMedGoogle Scholar
  29. Sanna G, Barone D, Midiri M, Finazzo M, Lagalla R: Ultrasonographic features with colour doppler, with computerized tomography and angiography in a case of abdominal Castleman's disease. Radiol Med. 1997, 93: 804-805.PubMedGoogle Scholar
  30. Singletary LA, Karcnik TJ, Abujudeh H: Hyaline vascular-type Castleman disease: a rare cause of a hypervascular retroperitoneal mass. Abdom Imaging. 2000, 25: 207-209. 10.1007/s002619910047.View ArticlePubMedGoogle Scholar
  31. Curciarello J, Castelleto R, Bardero R, Belloni P, Gelemur M, Castelleto E, Barbero R, Belloni P, Jmelnitzky AC: Hepatic sinusoidal dilatatiion associated to giant lymph node hyperplasia (Castleman's): a new case in a patient with periorbital xanthelasmas and history of ceoliac disease. J Clin Gastroenterol. 1998, 27: 76-78. 10.1097/00004836-199807000-00017.View ArticlePubMedGoogle Scholar
  32. Gonzalez Sanchez FJ, Landeras Alvaro RM, Encinas Gaspar MD, Napal Lecumberri S: Castleman's disease: isolated retroperitoneal mass. Report of a case. Arch Esp Urol. 1999, 52: 282-285.PubMedGoogle Scholar
  33. Schutz G, Gomille T, Lutzeler J, Christ F, Ulrich B: Lokalisierter Morbus Castleman. Diagnostische Schwierigkeiten einer chirurgisch therapierbaren erkrankung. Zentralbl Chir. 1999, 124: 1112-1115.PubMedGoogle Scholar
  34. Perez Garcia FJ, Martinez Gomez FJ, Fernandez Gomez JM, Regadera Sejas FJ, Rodriguez Martinez A, Snachez Trilla A, San Martin Blanco A, Seco Navedo MA: Enfermedad de Castleman de localisation retroperitoneal. Arch Esp Urol. 1999, 52: 388-392.PubMedGoogle Scholar
  35. Irsutti M, Paul JL, Selves J, Railhac JJ: Castleman disease: CT and MR imaging features of a retroperitoneal location in association with paraneoplastic pemphigus. Eur Radiol. 1999, 9: 1219-1221. 10.1007/s003300050821.View ArticlePubMedGoogle Scholar
  36. Parez N, Bader-Meunier B, Roy CC, Dommergues JP: Paediatric Castleman disease: report of seven cases and review of the literature. Eur J Pediatr. 1999, 158: 631-637. 10.1007/s004310051166.View ArticlePubMedGoogle Scholar
  37. Buchanan G, Chipman JJ, Hamilton BL, Daughaday WH: Angiomatous lymphoid hamartoma: inhibitory effects on erythropoiesis, growth and primary hemostasis. J Pediatr. 1981, 99: 382-388.View ArticlePubMedGoogle Scholar
  38. Ebisuno S, Yamauchi T, Fukatani T, Ohkawa T: Retroperitoneal Castleman's disease: A case report and brief review of tumours of the pararenal area. Urol Int. 1989, 44: 169-172.View ArticlePubMedGoogle Scholar
  39. Inoue Y, Nakamura H, Yamazaki K, Mizumoto S, Kokubu I, Mori H: Retroperitoneal Castleman's tumours of the hyaline vascular type: imaging study. Case report. Clin Imaging. 1992, 16: 239-242. 10.1016/0899-7071(92)90004-S.View ArticlePubMedGoogle Scholar
  40. Takihara H, Yamakawa G, Baba Y, Takahashi M, Ishihara T: Castleman disease unusual retroperitoneal location indistinguishable from malignant tumour in preoperative angiographic appearance. Urology. 1993, 41: 162-164. 10.1016/0090-4295(93)90173-8.View ArticlePubMedGoogle Scholar
  41. Feudis L, Carota G, Sargiacomo R, Traisci G: Retroperitoneal Castleman's disease. Ann Ital Med Int. 1998, 13: 117-120.PubMedGoogle Scholar
  42. Barret A, Bossavy JP, Stouff S, Gouzi JL, Gedeon A: Tumeurs de siège rétro-péritoneal et chirurgie des gros vaisseaux. Chirurgie. 1997, 122: 25-30.PubMedGoogle Scholar
  43. Okada S, Maeta H, Maeba T, Goda F, Mori S: Castleman disease of the pararenal retroperitoneum: report of a case. Surg Today. 1999, 29: 178-181. 10.1007/s005950050382.View ArticlePubMedGoogle Scholar
  44. Barki Y, Shadked G, Levy I: Mesenteric Castleman disease: sonographic diagnosis. J Clin Ultrasound. 1992, 20: 486-488.View ArticlePubMedGoogle Scholar
  45. Hung IJ, Kuo TT, Lin JN: New observations in a child with angiofollicular lymph node hyperplasia (Castleman's disease originated from the mesenteric root. Am J Pediatr Hematol Oncol. 1992, 14: 255-260.View ArticlePubMedGoogle Scholar
  46. Schroff VJ, Gilchrist BF, De Luca FG, McCombes HL, Wesselhoeft CW: Castleman's disease presenting as a paediatric surgical problem. J Pediatr Surg. 1995, 30: 745-747. 10.1016/0022-3468(95)90707-6.View ArticleGoogle Scholar
  47. Makipernaa A, Ashorn M, Arajarvi P, Hiltunen KM, Karikoski R: catsleman's disease of the mesentery in a child: a case of seven years' duration without typical X-ray findings. Med Pediatr Oncol. 1997, 28: 362-365. 10.1002/(SICI)1096-911X(199705)28:5<362::AID-MPO7>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
  48. De Heer-Groen TA, Prakken ABJ, Bax NMA, Van Dijken PJ: Iron therapy resistant microcytic anemia in a 13-year-old girl with Castleman disease. Eur J Pediatr. 1996, 155: 1015-1017. 10.1007/s004310050524.View ArticlePubMedGoogle Scholar
  49. Neerhout RC, Larson W, Mansur P: Mesenteric lymphoid hamartoma associated with hypoferremia, anaemia, growth failure and hyperglobulinemia. N Engl J Med. 1969, 280: 922-925.View ArticlePubMedGoogle Scholar
  50. Powell RW, Lightsey AL, Thomas WJ, Marsh WL: Castleman's disease in children. J Pediatr Surg. 1986, 21: 678-682.View ArticlePubMedGoogle Scholar
  51. Burke GJ, Wei J: Retroperitoneal mass and anaemia in an adolescent. Invest Radiol. 1992, 27: 748-750.View ArticlePubMedGoogle Scholar
  52. Volta S, Carella I, Gaeta M, Mantineo G, Blandino A: Castleman disease of the greater omentum. AJR. 1990, 154: 654-View ArticlePubMedGoogle Scholar
  53. Kiguchi H, Ishii T, Ishikawa Y, Masuda S, Asuwa N, Yamafuji K, Takahashi T: Castleman's disease of the abdomen and pelvis: Report of three cases and a review of the literature. J Gastroenterol. 1995, 30: 661-666.View ArticlePubMedGoogle Scholar
  54. Yebra M, Vargas JA, Menendez MJ, Cabrera JR, Diaz F, Diego FJ, Durantez A: Gastric Castleman's disease with a lupus-like circulating anticoagulant. Am J Gastroenterol. 1989, 84: 566-570.PubMedGoogle Scholar
  55. Rotman N, Sastre B, Fagniez PL: Medial pancretectomy for tumors of the neck of the pancreas. Surgery. 1993, 113: 532-535.PubMedGoogle Scholar
  56. Brossard G, Ollivier S, Pellegrin JL, Barbeau P, De mascarel A, Leng B: Tumeur pancreatique de Castleman révélée par une fièvre prolongée. Presse Med. 1992, 21: 86-PubMedGoogle Scholar
  57. Erkan N, Yildirim M, Selek E, Sayhan S: Peripancreatic Castleman disease. JOP. 2004, 5: 491-494.PubMedGoogle Scholar
  58. Chaulin B, Pontais C, Laurent F, De Mascarel, Drouillard J: Pancreatic Castleman disease: CT findings. Abdom Imaging. 1994, 19: 160-161. 10.1007/BF00203494.View ArticlePubMedGoogle Scholar
  59. Corbisier F, Ollier JC, Adloff M: Pancreatic localization of a Castleman tumour. Acta Chir Belg. 1993, 93: 227-229.PubMedGoogle Scholar
  60. Lepke RA, Pagani JJ: Pancreatic Castleman disease simulating pancreatic carcinoma on computed tomography. J Comput Assist Tomogr. 1982, 6: 1193-1195.View ArticlePubMedGoogle Scholar
  61. Rahmouni A, Golli M, Mathieu D, Anglade MC, Charlotte F, Vasile N: Castleman disease mimicking liver tumour: CT and MR features. J Comput Assist Tomogr. 1992, 16: 699-703.View ArticlePubMedGoogle Scholar
  62. Farkas E, Toth B, Besznyak I: Retroperitoneal Catsleman tumour. Orv Hetil. 1993, 134: 413-416.PubMedGoogle Scholar
  63. Peck D, Lum PA: Castleman disease in the porta hepatis: biphasic helical computed tomography. Can Assoc Radiol J. 1996, 47: 410-412.PubMedGoogle Scholar
  64. Cirillo RL, Vitellas KM, Deyoung BR, Bennett WF: Castleman's disease mimicking a hepatic neoplasm. Clin Imaging. 1998, 22: 124-129. 10.1016/S0899-7071(97)00096-X.View ArticlePubMedGoogle Scholar
  65. Debatin J, Spritzer C, Dunnick N: Castleman disease of the adrenal gland: MR imaging features. AJR. 1991, 157: 781-783.View ArticlePubMedGoogle Scholar
  66. Lattes R, Pachter MR: Benign lymphoid masses of probable hamartomatous nature. Cancer. 1962, 15: 197-214.View ArticlePubMedGoogle Scholar
  67. Daley M, Cornog JL: Pelvic retroperitoneal lymphoid hamartoma. J Urol. 1967, 97: 325-329.Google Scholar
  68. Boxer LA, Boxer GJ, Flair RC: Angiomatous lymphoid hamartoma associated with chronic anaemia ia, hypoferremia, hypergammaglobulinemia. J Pediatr. 1972, 81: 66-70.View ArticlePubMedGoogle Scholar
  69. Tsukamoto N, Iraha H, Matsuyama T: Giant lymph node hyperplasia. Report of two interesting cases. Gynecol Oncol. 1980, 9: 394-404. 10.1016/0090-8258(80)90051-7.View ArticlePubMedGoogle Scholar
  70. Luburich P, Nicolau C, Ayuso MC, Torra R, Clavero JA: Pelvic Castleman disease: Ct and MR appearance. J Comput Assist Tomogr. 1992, 16: 657-659.PubMedGoogle Scholar
  71. Isik AZ, Aydemir E, Zorlu G, Taner D, Adsay V, Nuhoglu G: Pelvic Castleman disease: an unusual mass. Aust N Z L Obbstet Gynaecol. 1994, 34: 118-120.View ArticleGoogle Scholar
  72. Ylinen K, Sarlomo-Rikala M, Laatikainen T: Pelvic Castleman disease mimicking an adnexal tumour. Obstet Gynecol. 1995, 85: 894-897. 10.1016/0029-7844(94)00335-B.View ArticlePubMedGoogle Scholar
  73. Schwartz A, Eid A, Sasson T, Cohen P, Durst AL, Rivkind AI: Pelvic giant lymph node hyperplasia (Castleman's disease): a surgical and radiological approach. Eur J Surg. 1996, 162: 993-996.PubMedGoogle Scholar
  74. Mondal AK, Basu N, Dasgupta A, Ghosh RN: Castleman disease of broad ligament. J Indian Med Assoc. 1996, 94: 453-454.PubMedGoogle Scholar
  75. Calvo Villas JM, Queizan JA, Lopez Elzaurdia C, Olvier C, Pardal E, Hernandez Martin JM: Enfermedad de Castleman de localizacion pelvica: a proposito de un caso. Sangre. 1996, 41: 241-243.PubMedGoogle Scholar
  76. Mac Donald SR, Lurain JR, Hoff F, Variakojis D, Fishman DA: Castleman disease presenting as a pelvic mass. Obstet Gynecol. 1996, 87: 875-877.Google Scholar
  77. Fields S, Bar-ziv J, Portnoy O, Sasson T, Sherman Y, Libson E: Radiologic spectrum of localised Castleman's disease. Isr J Med Sci. 1995, 31: 660-669.PubMedGoogle Scholar
  78. Kasantikul V, Panyavoravut V, Benjavongkulchai S, Panichabongse V: Castleman's disease: a clinicopathological study of 12 cases. J Med Assoc Thai. 1997, 80: 195-201.PubMedGoogle Scholar
  79. Murphy SP, Nathan MA, Karval MW: FDG-PET appearance of pelvic Castleman's disease. J Nucl Med. 1997, 38: 1211-1212.PubMedGoogle Scholar
  80. Taura T, Takashima S, Shakudo M, Kaminou T, Yamada R, Isoda K: Castleman's disease of the spleen: CT, MR imaging and angiographic findings. Eur J Radiol. 2000, 36: 11-15. 10.1016/S0720-048X(00)00173-X.View ArticlePubMedGoogle Scholar
  81. Papanicolaou N, Yoder IC, Lee MJ: Primary retroperitoneal neoplasms: How close can we come in making the correct diagnosis?. Urol Radiol. 1992, 14: 221-228.View ArticlePubMedGoogle Scholar
  82. Bartkowski DP, Ferrigni RG: Castleman's disease: an unusual retroperitoneal mass. J Urol. 1988, 139: 118-120.PubMedGoogle Scholar
  83. Storm F, Mahvi D: Diagnosis and management of retroperitoneal soft-tissue sarcoma. Ann Surg. 1991, 214: 2-10.PubMed CentralView ArticlePubMedGoogle Scholar
  84. Bories-Azeau A, Guivarch M: Les tumeurs rétropéritoneales primitives 683 observations. J Chir. 1981, 118: 591-600.Google Scholar
  85. Cohan RH, Baker ME, Cooper C, Moore JO, Saeed M, Dunnick NR: Computed tomography of primary retroperitoneal malignancies. J Comput Assit Tomogr. 1988, 12: 804-810.View ArticleGoogle Scholar
  86. Lane RH, Stephens DH, Reiman HM: Primary retroperitoneal neoplasms: CT Findings in 90 cases with clinical and pathologic correlation. AJR. 1989, 152: 83-89.View ArticlePubMedGoogle Scholar
  87. Constance Parkinson M, Chabrel CM: Clinicopathological features of retroperitoneal tumours. Br J Urol. 1984, 56: 17-23.View ArticleGoogle Scholar
  88. Meyer L, Gibbons D, Ashfaq R, Vuitch F, Saboorian MH: Fine-needle aspiration findings in Castleman's disease. Diagn Cytopathol. 1999, 21: 57-60. 10.1002/(SICI)1097-0339(199907)21:1<57::AID-DC16>3.0.CO;2-A.View ArticlePubMedGoogle Scholar
  89. Lundstedt C, Stridbeck H, Andersson R, Tranberg KG, Andren-Sandberg A: Tumor seeding occuring after fine-needle biopsy of abdominal malignancies. Acta Radiol. 1991, 32: 518-520.View ArticlePubMedGoogle Scholar
  90. Skolnik G, Wiklund L-M, Risberg B: Castleman's tumor with retroperitoneal location: a malignant appearing benign tumor. J Surg Oncol. 1985, 28: 153-155.View ArticlePubMedGoogle Scholar
  91. Lerza R, Castello G, Truini M, Ballarino P, Tredici S, Cavallini D, Pannacciulli I: Splenectomy induced complete remission in a patient with multicentric Castleman's disease and autoimmune haemolytic anaemia. Ann Hematol. 1999, 78: 193-196. 10.1007/s002770050500.View ArticlePubMedGoogle Scholar
  92. Horster S, Jung C, Zietz C, Cohen CD, Siebeck M, Goebel FD: AIDS, multicentric Castleman's disease, and plamablastic leukemia: report of a long-term survival. Infection. 2004, 32: 296-298. 10.1007/s15010-004-3148-3.View ArticlePubMedGoogle Scholar

Copyright

© Bucher et al; licensee BioMed Central Ltd. 2005

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement